58 related articles for article (PubMed ID: 10994145)
1. [Bone scan and prostate cancer].
Letaief B; Boughattas S; Hassine H; Essabbah H
Ann Urol (Paris); 2000 Aug; 34(4):254-65. PubMed ID: 10994145
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans.
Murphy GP; Snow PB; Brandt J; Elgamal A; Brawer MK
Prostate; 2000 Feb; 42(2):145-9. PubMed ID: 10617872
[TBL] [Abstract][Full Text] [Related]
3. [The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate].
Hoefman E; Hulshof MC; de Reijke TM; Bruijnes E; Redekop WK; van Straalen JP
Ned Tijdschr Geneeskd; 1998 May; 142(20):1142-6. PubMed ID: 9623236
[TBL] [Abstract][Full Text] [Related]
4. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
5. [Cancer of the prostate: value of bone scintigraphy. Point of view].
Lumbroso J; Guermazi F; Wibault P; Henry-Amar M; Travagli JP
Bull Cancer; 1985; 72(5):436-41. PubMed ID: 3907735
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
[TBL] [Abstract][Full Text] [Related]
7. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications.
Oesterling JE
Urol Clin North Am; 1993 Nov; 20(4):705-11. PubMed ID: 7505979
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
9. [Value of PSA in the staging of prostatic cancer].
Sassine AM; Schulman C
Acta Urol Belg; 1992; 60(3):49-59. PubMed ID: 1283504
[TBL] [Abstract][Full Text] [Related]
10. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer.
Stock RG; Stone NN; Ianuzzi C; Unger P
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888
[TBL] [Abstract][Full Text] [Related]
11. [The role of bone scintigraphy and its value in the staging and follow up of prostatic carcinoma].
Adám E; Gervain M; Rajtár M; Oszlánczi J; Csernay L; Scultéty S
Orv Hetil; 1989 Feb; 130(7):335-40. PubMed ID: 2645558
[TBL] [Abstract][Full Text] [Related]
12. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
13. Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level.
Schwartz LH; LaTrenta LR; Bonaccio E; Kelly WK; Scher HI; Panicek DM
Radiology; 1998 Sep; 208(3):735-8. PubMed ID: 9722854
[TBL] [Abstract][Full Text] [Related]
14. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
[TBL] [Abstract][Full Text] [Related]
15. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation for clinical staging parameters of prostate neoplasm].
Zhong CY; Liu M; Zhang LQ; Wan B
Zhonghua Nan Ke Xue; 2003 Apr; 9(2):100-2. PubMed ID: 12749126
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
Slovin SF; Scher HI; Divgi CR; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson SM
Clin Cancer Res; 1998 Mar; 4(3):643-51. PubMed ID: 9533532
[TBL] [Abstract][Full Text] [Related]
18. [Staging in prostate carcinoma].
Trinkler FB; Böni RA; Krestin GP
Ther Umsch; 1995 Jun; 52(6):399-404. PubMed ID: 7604393
[TBL] [Abstract][Full Text] [Related]
19. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
20. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
